We are live on ! Find out more

Novavax

NVAX

Market cap $1.58B

9.59 USD

+0.17

1.8%

At close Updated Sep 14, 4:00 PM EDT

Pre-market

After hours

9.57

-0.02

0.21%

1 day

1.8%

5 days

-5.05%

1 month

19.13%

3 months

4.13%

6 months

-4.86%

Year to date

34.5%

1 year

18.69%

5 years

-95.91%

10 years

-94.23%

About: Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.

Employees: 749

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 43.8%

Neutral 34.4%

Negative 21.9%

Zacks Investment Research

Novavax (NVAX) Laps the Stock Market: Here's Why

In the most recent trading session, Novavax (NVAX) closed at $9.42, indicating a +1.29% shift from the previous trading day.

Novavax (NVAX) Laps the Stock Market: Here's Why

Novavax Highlights Sanofi, Pfizer Catalysts in Matrix-M Platform Pivot

Novavax NASDAQ: NVAX executives outlined the company's transition from a COVID-19 vaccine-focused business toward a partnership-driven model centered on its Matrix-M adjuvant technology, with near-term attention on Sanofi's commercial rollout of NUVAXOVID, combination vaccine development and early oncology research.

Novavax Highlights Sanofi, Pfizer Catalysts in Matrix-M Platform Pivot

Novavax, Inc. (NVAX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Novavax, Inc. (NVAX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Novavax, Inc. (NVAX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Novavax Highlights Matrix-M Licensing Push, Oncology Ambitions at Cantor Conference

Novavax NASDAQ: NVAX outlined its strategy to expand the use of its Matrix-M adjuvant platform through licensing partnerships, internal research programs and commercialization alliances, with management highlighting progress in infectious disease vaccines and early oncology work at the Cantor Healthcare Conference.

Novavax Highlights Matrix-M Licensing Push, Oncology Ambitions at Cantor Conference

Novavax, Inc. (NVAX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

Novavax, Inc. (NVAX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

Novavax, Inc. (NVAX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

Novavax to Participate in September Investor Conferences

GAITHERSBURG, Md., Sept. 2, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that company management will participate in the following upcoming investor conferences: 2026 Cantor Global Healthcare Conference, New YorkFireside chat on Wednesday, September 9, 2026, at 9:45 a.m.

Novavax to Participate in September Investor Conferences

Novavax Stock Rises Despite No Confirmed News Behind the Matrix-M Rumor

Novavax Inc. (NASDAQ:NVAX) shares are trading higher. Strength may be due to an increase in investor attention related to an unconfirmed rumor suggesting that Matrix-M has a favorable safety profile with mostly mild-to-moderate, self-limiting side effects.

Novavax Stock Rises Despite No Confirmed News Behind the Matrix-M Rumor

24/7 Wall Street

Novavax Jumps 6% on Matrix-M Oncology Speculation: Is the Royalty Model the Real Story?

Retail traders are treating Novavax as a cancer-vaccine play today, but the price action shows a single-name bid rather than a sector move. Novavax (NASDAQ:NVAX) stock is up 6% to $9.90 in midday trading.

Novavax Jumps 6% on Matrix-M Oncology Speculation: Is the Royalty Model the Real Story?

Novavax Stock Climbs Monday: What's Going On?

Shares of Novavax Inc. (NASDAQ:NVAX) are trading higher Monday morning. The stock is extending its 30% monthly gains as investors respond positively to regulatory approvals across major jurisdictions for its updated protein-based COVID-19 vaccine ahead of the 2026–2027 autumn vaccination campaign, alongside broader sector strength bolstered by positive late-stage oncology clinical trial results across the biotech landscape.

Novavax Stock Climbs Monday: What's Going On?

Novavax's Partnership Strategy Continues to Deliver with XFG-adapted Nuvaxovid™ Approvals in the U.S., EU and Japan for 2026-2027 Vaccination Season

COVID-19 remains a public health challenge, particularly among older adults and high-risk populations 1 Novavax's partners are ready to bring its protein-based, non-mRNA vaccine with a favorable tolerability profile to global markets, providing an important option for healthcare providers and patients GAITHERSBURG, Md., Aug. 28, 2026 /PRNewswire/ -- Novavax, Inc.'s (Nasdaq: NVAX) partners have received approvals for the Nuvaxovid™ formulation to target the SARS-CoV-2 XFG variant for the 2026-2027 vaccination season in major markets including the U.S., European Union (EU) and Japan.

Novavax's Partnership Strategy Continues to Deliver with XFG-adapted Nuvaxovid™ Approvals in the U.S., EU and Japan for 2026-2027 Vaccination Season

See News Rankings

Price charts implemented using Lightweight Charts™